Mesothelin HiT TCR-T / Adaptimmune, Astellas - LARVOL DELTA

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model (GlobeNewswire) - "Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells...HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies."

Preclinical • Oncology • Solid Tumor

Adaptimmune Reports First Quarter Financial Results and Business Update (GlobeNewswire) - “We will present initial data at ASCO from our SPEARHEAD-1 trial that will support BLA submission in 2022...At ASGCT next week, we will present preclinical data from our first HiT product targeting mesothelin. Results indicate that this HiT works as well or better than similar cell therapy constructs targeting the same antigen in in vitro killing assays as well as an animal model."

BLA • Clinical data • P2 data • Preclinical • Oncology • Sarcoma

[VIRTUAL] In Vitro Selection and Engineering of a Human Leukocyte Antigen-Independent T-Cell Receptor Recognizing Human Mesothelin (ASGCT 2021) - " The mesothelin HiT showed an affinity for recombinant mesothelin in the natural range for pHLA-TCR interactions and demonstrated activation of T-cells in an antigen-dependent manner... This study demonstrated that a human TCR can target tumor-associated antigens without the need for HLA recognition, and in the context of autologous cell therapy, should allow a wider patient population to be treated. The use of the natural TCR affinity and T-cell signaling mechanisms may be advantageous when compared to chimeric antigen receptors. Additionally, our study showed T-cell activation and tumor cell killing can be modulated by optimizing the HiT’s affinity, a key step in developing a safe immunotherapy product."

IO biomarker • Preclinical • Oncology • MSLN

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT (GlobeNewswire) - "Adaptimmune Therapeutics plc...will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference."

Preclinical • Oncology